Banks - Regional
Build Your Comparison
Side-by-side financial analysisStock Comparison
ECBK vs NBTB vs CARE vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Banks - Regional
Banks - Diversified
ECBK vs NBTB vs CARE vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Banks - Regional | Banks - Regional | Banks - Regional | Banks - Diversified |
| Market Cap | $178M | $2.44B | $686M | $908.57B |
| Revenue (TTM) | $80M | $902M | $252M | $280.33B |
| Net Income (TTM) | $8M | $169M | $31M | $57.05B |
| Gross Margin | 39.9% | 73.6% | 61.2% | 60.0% |
| Operating Margin | 13.1% | 24.3% | 15.9% | 25.9% |
| Forward P/E | 21.6x | 11.2x | 5.7x | 14.6x |
| Total Debt | $285M | $327M | $179M | $942.38B |
| Cash & Equiv. | $95M | $185M | $105M | $343.34B |
ECBK vs NBTB vs CARE vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 22 | Jun 26 | Return |
|---|---|---|---|
| ECB Bancorp, Inc. (ECBK) | 100 | 145.3 | +45.3% |
| NBT Bancorp Inc. (NBTB) | 100 | 115.1 | +15.1% |
| Carter Bankshares, … (CARE) | 100 | 221.9 | +121.9% |
| JPMorgan Chase & Co. (JPM) | 100 | 281.9 | +181.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ECBK vs NBTB vs CARE vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ECBK carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 16.5%, EPS growth 95.8%
- 16.5% NII/revenue growth vs JPM's 3.3%
- Efficiency ratio 0.3% vs NBTB's 0.5% (lower = leaner)
- Beta 0.44 vs JPM's 0.87, lower leverage
NBTB is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 13 yrs, beta 0.73, yield 3.1%
- Lower volatility, beta 0.73, Low D/E 17.3%, current ratio 1.60x
- Beta 0.73, yield 3.1%, current ratio 1.60x
- NIM 3.1% vs ECBK's 2.0%
CARE is the clearest fit if your priority is momentum.
- +86.8% vs NBTB's +20.5%
JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 481.2% 10Y total return vs CARE's 150.2%
- PEG 0.83 vs NBTB's 1.59
- PEG 0.83 vs 1.59
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.5% NII/revenue growth vs JPM's 3.3% | |
| Value | PEG 0.83 vs 1.59 | |
| Quality / Margins | Efficiency ratio 0.3% vs NBTB's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.44 vs JPM's 0.87, lower leverage | |
| Dividends | 3.1% yield, 13-year raise streak, vs JPM's 1.8%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +86.8% vs NBTB's +20.5% | |
| Efficiency (ROA) | Efficiency ratio 0.3% vs NBTB's 0.5% |
ECBK vs NBTB vs CARE vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ECBK vs NBTB vs CARE vs JPM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 1 of 6 categories
ECBK leads 1 • NBTB leads 0 • CARE leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 3525.9x ECBK's $80M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ECBK's 9.8%.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $80M | $902M | $252M | $280.3B |
| EBITDAEarnings before interest/tax | $11M | $241M | $46M | $81.4B |
| Net IncomeAfter-tax profit | $8M | $169M | $31M | $57.0B |
| Free Cash FlowCash after capex | $9M | $225M | $30M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +39.9% | +73.6% | +61.2% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +13.1% | +24.3% | +15.9% | +25.9% |
| Net MarginNet income ÷ Revenue | +9.8% | +18.8% | +12.5% | +20.4% |
| FCF MarginFCF ÷ Revenue | +11.3% | +24.9% | +11.9% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +82.4% | +39.5% | +8.3% | +16.0% |
Valuation Metrics
Evenly matched — ECBK and NBTB and JPM each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 14.0x trailing earnings, NBTB trades at a 37% valuation discount to CARE's 22.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs NBTB's 1.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $178M | $2.4B | $686M | $908.6B |
| Enterprise ValueMkt cap + debt − cash | $368M | $2.6B | $759M | $1.51T |
| Trailing P/EPrice ÷ TTM EPS | 21.61x | 14.02x | 22.11x | 16.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.18x | 5.67x | 14.60x |
| PEG RatioP/E ÷ EPS growth rate | 1.16x | 1.99x | — | 0.92x |
| EV / EBITDAEnterprise value multiple | 35.47x | 10.70x | 18.98x | 18.52x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 2.81x | 2.69x | 3.25x |
| Price / BookPrice ÷ Book value/share | 0.98x | 1.25x | 1.66x | 2.51x |
| Price / FCFMarket cap ÷ FCF | 19.80x | 11.13x | 21.57x | 9.01x |
Profitability & Efficiency
Evenly matched — NBTB and CARE and JPM each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $5 for ECBK. NBTB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CARE scores 8/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.6% | +9.5% | +7.6% | +15.9% |
| ROA (TTM)Return on assets | +0.5% | +1.1% | +0.7% | +1.3% |
| ROICReturn on invested capital | +1.8% | +7.9% | +5.7% | +4.5% |
| ROCEReturn on capital employed | +2.3% | +2.4% | +1.5% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 8 | 5 |
| Debt / EquityFinancial leverage | 1.66x | 0.17x | 0.43x | 2.60x |
| Net DebtTotal debt minus cash | $190M | $142M | $73M | $599.0B |
| Cash & Equiv.Liquid assets | $95M | $185M | $105M | $343.3B |
| Total DebtShort + long-term debt | $285M | $327M | $179M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 0.22x | 1.05x | 0.39x | 0.74x |
Total Returns (Dividends Reinvested)
Evenly matched — CARE and JPM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $23,985 today (with dividends reinvested), compared to $14,414 for ECBK. Over the past 12 months, CARE leads with a +86.8% total return vs NBTB's +20.5%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs NBTB's 14.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +17.3% | +14.0% | +59.9% | +0.8% |
| 1-Year ReturnPast 12 months | +34.3% | +20.5% | +86.8% | +20.9% |
| 3-Year ReturnCumulative with dividends | +55.6% | +49.9% | +103.8% | +138.8% |
| 5-Year ReturnCumulative with dividends | +44.1% | +46.9% | +139.8% | +135.5% |
| 10-Year ReturnCumulative with dividends | +44.1% | +103.1% | +150.2% | +481.2% |
| CAGR (3Y)Annualised 3-year return | +15.9% | +14.5% | +26.8% | +33.7% |
Risk & Volatility
ECBK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ECBK is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than JPM's 0.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ECBK currently trades 99.1% from its 52-week high vs NBTB's 95.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.45x | 0.73x | 0.50x | 0.87x |
| 52-Week HighHighest price in past year | $20.50 | $48.81 | $31.40 | $338.09 |
| 52-Week LowLowest price in past year | $14.82 | $39.20 | $16.27 | $269.72 |
| % of 52W HighCurrent price vs 52-week peak | +99.1% | +95.6% | +98.6% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 59.4 | 51.0 | 76.8 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 11K | 277K | 323K | 7.4M |
Analyst Outlook
Evenly matched — NBTB and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NBTB as "Hold", CARE as "Hold", JPM as "Buy". Consensus price targets imply 4.5% upside for JPM (target: $340) vs -7.9% for CARE (target: $29). For income investors, NBTB offers the higher dividend yield at 3.06% vs JPM's 1.83%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | — | $46.00 | $28.50 | $339.75 |
| # AnalystsCovering analysts | — | 10 | 5 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% | — | +1.8% |
| Dividend StreakConsecutive years of raises | — | 13 | 0 | 15 |
| Dividend / ShareAnnual DPS | — | $1.43 | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.6% | +0.4% | +2.9% | +3.8% |
JPM leads in 1 of 6 categories (Income & Cash Flow). ECBK leads in 1 (Risk & Volatility). 4 tied.
ECBK vs NBTB vs CARE vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ECBK or NBTB or CARE or JPM a better buy right now?
For growth investors, ECB Bancorp, Inc.
(ECBK) is the stronger pick with 16. 5% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). NBT Bancorp Inc. (NBTB) offers the better valuation at 14. 0x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ECBK or NBTB or CARE or JPM?
On trailing P/E, NBT Bancorp Inc.
(NBTB) is the cheapest at 14. 0x versus Carter Bankshares, Inc. at 22. 1x. On forward P/E, Carter Bankshares, Inc. is actually cheaper at 5. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus NBT Bancorp Inc. 's 1. 59x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ECBK or NBTB or CARE or JPM?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +139. 8%, compared to +44. 1% for ECB Bancorp, Inc. (ECBK). Over 10 years, the gap is even starker: JPM returned +481. 2% versus ECBK's +44. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ECBK or NBTB or CARE or JPM?
By beta (market sensitivity over 5 years), ECB Bancorp, Inc.
(ECBK) is the lower-risk stock at 0. 45β versus JPMorgan Chase & Co. 's 0. 87β — meaning JPM is approximately 96% more volatile than ECBK relative to the S&P 500. On balance sheet safety, NBT Bancorp Inc. (NBTB) carries a lower debt/equity ratio of 17% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ECBK or NBTB or CARE or JPM?
By revenue growth (latest reported year), ECB Bancorp, Inc.
(ECBK) is pulling ahead at 16. 5% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: ECB Bancorp, Inc. grew EPS 95. 8% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ECBK or NBTB or CARE or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 9. 8% for ECB Bancorp, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 13. 1% for ECBK. At the gross margin level — before operating expenses — NBTB leads at 72. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ECBK or NBTB or CARE or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus NBT Bancorp Inc. 's 1. 59x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Carter Bankshares, Inc. (CARE) trades at 5. 7x forward P/E versus 14. 6x for JPMorgan Chase & Co. — 8. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JPM: 4. 5% to $339. 75.
08Which pays a better dividend — ECBK or NBTB or CARE or JPM?
In this comparison, NBTB (3.
1% yield), JPM (1. 8% yield) pay a dividend. ECBK, CARE do not pay a meaningful dividend and should not be held primarily for income.
09Is ECBK or NBTB or CARE or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, ECBK: +44. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ECBK and NBTB and CARE and JPM?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ECBK is a small-cap high-growth stock; NBTB is a small-cap deep-value stock; CARE is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. NBTB, JPM pay a dividend while ECBK, CARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.